Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference
Rhea-AI Summary
Altimmune (NASDAQ: ALT) announced that its management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference.
The session is scheduled for Wednesday, December 3, 2025 at 2:30 p.m. ET and will be available via webcast. Investors can access the webcast through the Events section of Altimmune's website.
Positive
- None.
Negative
- None.
News Market Reaction – ALT
In the Nov 26 session, ALT gained 0.58%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 01 | CEO transition | Negative | -6.3% | Leadership change with CEO succession and timeline for outgoing CEO. |
| Nov 26 | Investor conference | Neutral | +0.6% | Announcement of participation in Piper Sandler healthcare conference webcast. |
| Nov 11 | Clinical data update | Positive | +0.5% | Publication and presentation of positive 24-week IMPACT Phase 2b MASH data. |
| Nov 07 | AI fibrosis analysis | Positive | +4.3% | AI-based analysis showing significant fibrosis reductions vs placebo in MASH. |
| Nov 06 | Earnings and updates | Positive | +5.1% | Q3 2025 financials, strong cash balance, loan amendment, and clinical milestones. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Across the last five news events, ALT’s share price consistently moved in the same direction as the perceived news tone, with positive clinical and financing updates followed by gains and leadership or neutral items seeing limited or negative reaction.
Over recent months, Altimmune reported several key developments. Q3 2025 results on Nov 6 highlighted $210.8M in liquidity, a $19.0M net loss, and expansion of its Hercules facility, with shares rising about 5%. Subsequent AI-based fibrosis data from the IMPACT Phase 2b trial on Nov 7 and The Lancet publication on Nov 11 both showed favorable MASH outcomes and modest positive price moves. The Piper Sandler conference participation on Nov 26 prompted a small gain, while the CEO transition news on Dec 1 coincided with a larger decline.
Key Terms
cardiometabolic medical
peptide-based therapeutics medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
GAITHERSBURG, Md., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company’s management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference. Details are as follows:
Conference: Piper Sandler 37th Annual Healthcare Conference
Date/Time: Wednesday, December 3, 2025 at 2:30 p.m. ET
The session will be webcast and can be accessed by visiting the Events section of the Altimmune website.
About Altimmune
Altimmune is a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company’s lead product candidate is pemvidutide, a glucagon/GLP-1 dual receptor agonist for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on X
Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com
Media Contact:
Savannah Valade
Real Chemistry
altimmune@realchemistry.com
This press release was published by a CLEAR® Verified individual.
